Global Leading Market Research Publisher QYResearch announces the release of its latest report “Lung Cancer PCR Panel – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032.”
The clinical management of non-small cell lung cancer has been fundamentally transformed by the discovery of actionable genetic alterations—mutations in EGFR, KRAS, BRAF, and rearrangements in ALK and ROS1—that predict response to specific targeted therapies. For oncologists, pathologists, and molecular diagnostics laboratory directors, the lung cancer PCR panel serves as the critical diagnostic bridge between tumor biology and therapeutic decision-making. The challenge is delivering rapid, multiplexed genotyping results from increasingly limited tissue specimens while maintaining the sensitivity to detect low-frequency variants in heterogeneous tumors or circulating tumor DNA. This market research report, grounded in historical analysis (2021-2025) and rigorous forecast calculations (2026-2032), delivers a comprehensive analysis of the global lung cancer PCR panel industry, including market size quantification, market share distribution, and forward-looking development forecasts.
Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6071372/lung-cancer-pcr-panel
Market Sizing: Biomarker-Driven Therapy Adoption Anchors Growth
The global market for Lung Cancer PCR Panel was estimated to be worth USD 581 million in 2025 and is projected to reach USD 874 million by 2032, expanding at a compound annual growth rate of 6.1% throughout the forecast period. This growth trajectory reflects the progressive expansion of genomically-guided therapy in lung cancer. The increasing number of approved targeted therapies—each requiring companion diagnostic testing for the corresponding biomarker—directly expands PCR panel utilization. The American Society of Clinical Oncology and the College of American Pathologists now recommend routine testing for a minimum panel of genes in all advanced non-squamous NSCLC patients, establishing a clinical testing standard that drives demand.
Product Definition: Multiplexed Genotyping for Therapeutic Decision-Making
A Lung Cancer PCR Panel is a molecular diagnostic tool that uses polymerase chain reaction technology to simultaneously detect multiple gene mutations or fusions associated with lung cancer. This panel typically includes key genes such as EGFR, KRAS, ALK, ROS1, and BRAF, which are crucial for understanding tumor biology, guiding targeted therapy, and predicting prognosis. By analyzing DNA or RNA extracted from tumor tissue or liquid biopsy samples, the PCR panel provides rapid and highly sensitive results, aiding in the selection of personalized treatment strategies. The technology’s speed—delivering results within hours rather than days—and minimal sample requirements make it an essential component in the clinical management of lung cancer.
Technology Dynamics: PCR, NGS, and Liquid Biopsy Complementarity
The market segments by technology into NGS, Liquid Biopsy, and Other platforms. While next-generation sequencing offers broader genomic coverage, PCR panels maintain a distinct competitive position for rapid turnaround, lower cost, and established regulatory approvals with specific targeted therapies. Liquid biopsy-based PCR testing represents the highest-growth segment, enabling non-invasive genotyping from plasma samples when tissue is insufficient or unobtainable. By application, the market spans Hospitals, Third-party Independent Laboratories, and Other settings. Key participants profiled include Thermo Fisher Scientific, Roche, Qiagen, Bio-Rad Laboratories, Guardant Health, and Illumina.
Exclusive Observation: The Tissue-Liquid Testing Integration Paradigm
An exclusive industry observation concerns the emerging clinical paradigm of integrated tissue and liquid biopsy PCR testing. Rather than competing modalities, tissue-based and plasma-based PCR panels are increasingly deployed as complementary tools: tissue testing provides definitive genotyping at diagnosis, while liquid biopsy testing enables serial monitoring for acquired resistance mutations during targeted therapy. This integrated paradigm simultaneously expands the total PCR panel testing volume per patient and creates demand for harmonized platforms where results from both specimen types can be interpreted within a common analytical framework—a competitive advantage for manufacturers offering both tissue and liquid biopsy PCR solutions.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
